FierceBiotech 2026-01-22 Corcept racks up phase 3 cancer win to bounce back from FDA Cushing's rejection
FierceBiotech 2026-01-22 Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug
FierceBiotech 2026-01-22 Hoth strikes back against cancer drug skin toxicities, but share price stays frozen
FierceBiotech 2026-01-21 Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
FierceBiotech 2026-01-21 FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma
FierceBiotech 2026-01-21 IO mulls more layoffs months after halving head count in wake of cancer vaccine setback
FierceBiotech 2026-01-21 Touching base: Beam CEO on gene editing biotech's 'big push' for in vivo delivery
FierceBiotech 2026-01-21 Nkarta’s CEO wore head-to-toe pink at JPM. Here’s why it matters more than ever
FierceBiotech 2026-01-20 Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years
FierceBiotech 2026-01-20 Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs
FierceBiotech 2026-01-20 Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis
FierceBiotech 2026-01-20 Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark
FierceBiotech 2026-01-20 GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair